{"name":"Kissei Pharmaceutical Co., Ltd.","slug":"kissei-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"kissei.com","description":"Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company with a focus on developing innovative treatments in various therapeutic areas. The company has a pipeline of 24 drugs, including JR-131 and PA21, which are currently in Phase 3 trials.","hq":"Matsumoto","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"neuroscience","drugs":[{"name":"KCT-0809","genericName":"KCT-0809","slug":"kct-0809","indication":"Type 2 diabetes","status":"phase_2"},{"name":"KPS-0373","genericName":"KPS-0373","slug":"kps-0373","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"KPS-0373, Low dose","genericName":"KPS-0373, Low dose","slug":"kps-0373-low-dose","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"MR13A9","genericName":"MR13A9","slug":"mr13a9","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"PA21","genericName":"PA21","slug":"pa21","indication":"Type 2 diabetes mellitus","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"KAD-1229","genericName":"KAD-1229","slug":"kad-1229","indication":"Hypertension","status":"marketed"},{"name":"KLH-2109","genericName":"KLH-2109","slug":"klh-2109","indication":"Hypertension","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"KUX-1151","genericName":"KUX-1151","slug":"kux-1151","indication":"Other","status":"phase_2"},{"name":"KWA-0711","genericName":"KWA-0711","slug":"kwa-0711","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"JR-131","genericName":"JR-131","slug":"jr-131","indication":"FGFR-altered solid tumors (in clinical development)","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"KPS-0373, High dose","genericName":"KPS-0373, High dose","slug":"kps-0373-high-dose","indication":"Chronic pain (Phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"KAD-1229","genericName":"KAD-1229","slug":"kad-1229","phase":"marketed","mechanism":"KAD-1229 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure.","indications":["Hypertension"],"catalyst":""},{"name":"KUX-1151","genericName":"KUX-1151","slug":"kux-1151","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KWA-0711","genericName":"KWA-0711","slug":"kwa-0711","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JR-131","genericName":"JR-131","slug":"jr-131","phase":"phase_3","mechanism":"JR-131 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to treat FGFR-driven cancers.","indications":["FGFR-altered solid tumors (in clinical development)"],"catalyst":""},{"name":"KCT-0809","genericName":"KCT-0809","slug":"kct-0809","phase":"phase_2","mechanism":"KCT-0809 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"KLH-2109","genericName":"KLH-2109","slug":"klh-2109","phase":"marketed","mechanism":"KLH-2109 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure.","indications":["Hypertension"],"catalyst":""},{"name":"KPS-0373","genericName":"KPS-0373","slug":"kps-0373","phase":"phase_3","mechanism":"KPS-0373 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"KPS-0373, High dose","genericName":"KPS-0373, High dose","slug":"kps-0373-high-dose","phase":"phase_3","mechanism":"KPS-0373 is a selective TRPV1 antagonist that blocks pain signaling through the transient receptor potential vanilloid 1 channel.","indications":["Chronic pain (Phase 3 development)"],"catalyst":""},{"name":"KPS-0373, Low dose","genericName":"KPS-0373, Low dose","slug":"kps-0373-low-dose","phase":"phase_3","mechanism":"KPS-0373 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"MR13A9","genericName":"MR13A9","slug":"mr13a9","phase":"phase_3","mechanism":"MR13A9 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"PA21","genericName":"PA21","slug":"pa21","phase":"phase_3","mechanism":"PA21 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.","indications":["Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOYXhDcFF2bzA1cXF4MDFHT19pY0xFNTZNX0I5R2xPcUJXejdrUVhGOW8xWlR0WHFHblJqSFJ2S3hPU3IxNy1lWkxXRjQyMzRJTm5aLWJHX0wzWG5wTnhQVGMyT0xDSDRWRTkxemNLbUo0dUhRREZKSHVrLVVfTXJOMWpaUGlwbkFaVlloRWVtdHo0ZnFHdG9MeXdjVXZZWlpfWlJLTUtnNFd3THloUllsLW9RNFRwUFNwc3NUbVpFQnZqakxu?oc=5","date":"2026-03-20","type":"pipeline","source":"AD HOC NEWS","summary":"Kissei Pharmaceutical Aktie surges on Icelty launch for uterine fibroids in Japan - AD HOC NEWS","headline":"Kissei Pharmaceutical Aktie surges on Icelty launch for uterine fibroids in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPZnh4by1ub1ZXaXR6NXY3cEZWc2xaZHlwOGJkVHRHdkx0Mk5GWXlTUDhXRnRPdWtiZkU2V0ZsTGNaTWxSMUNGR3p6bDgzeU54ZDF0cW5hVmxJLWRtZTNWYTh2UzdfVVZMcWkybktkWUR1RC02YVp6NEdBSUlMcFlZRjYwendMTEJUZ0F3RVU2Sy1mSTZrRTNYUUIxM2U1NnJ3dlNhenhISVMzRjg0SThpMGY1SUcyODJS?oc=5","date":"2026-03-14","type":"pipeline","source":"AD HOC NEWS","summary":"Kissei Pharmaceutical Stock (ISIN: JP3212800001) Holds Steady Amid Japanese Pharma Sector Pressures - AD HOC NEWS","headline":"Kissei Pharmaceutical Stock (ISIN: JP3212800001) Holds Steady Amid Japanese Pharma Sector Pressures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOU3lsNjVRVXowSGdWZ0plSWhhWUZoWEd0VERldmlWNUNXZl9PMHlqenBnRE9ZR2VTZ1JvMUZFWjllb0NFTnl4LUhBRGxFOVFwTDgzWlBjcWg3VlFVQXhtZDRoZWVrZHVGSnFyN01KR1FJcW4xODlIZkFiWko2M01OSXRMcmhVSVN2b0J2ZmVZVEU1STV5N2dQbjNtdHlwSmdpUjhIQVlNZEM2SXpKVGdiWThuWlBPeUNYZ2RXMjJJVHhSdmVmRWI0ejZuTDl3OXpGbmg1N0UzZExwbjBEb0w4dA?oc=5","date":"2026-02-10","type":"pipeline","source":"Barchart.com","summary":"The Hyperphosphatemia Market was valued at approximately USD 4 billion in 2023, according to DelveInsight - Barchart.com","headline":"The Hyperphosphatemia Market was valued at approximately USD 4 billion in 2023, according to DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOT1hTVnZreC1XUWg0Z29KdkdXazVHUmEwNFRoaG1KRHZaRFRoMzFIeUVDME5wSzRPV0EzTUMtX0N3NGljQVNmMy1lZEdfSHAwb0Ffd3dGQThwZHJmRnBXQTMtNVFrd1hNM2ZzMG0zY0FFdC1Yai0wal95MWxzVW5idHdKWGhBc01Td0NDN0Rsdm5sR1ZrZkQxMFNtWU1DWWNWVUswU2JlbFB4bURxb0Z6Yw?oc=5","date":"2026-01-07","type":"deal","source":"Bloomberg.com","summary":"Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal - Bloomberg.com","headline":"Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQVDBxdGxuaktXVmluVlRNMEI5c3dVZzVLWExxVm93OVduLW9yS0c0Sm5Qa3VwcU0xNWRWemdZTE1RWEJhR016eXYtZWQyVFFFZnhHNU42aEhEdE9vN1d0VzFuelZrQ2o2Rkw4UXRKTm5KUkk4M21RRDZlb0lLZXVWRw?oc=5","date":"2025-11-10","type":"pipeline","source":"Fortune Business Insights","summary":"Uterine Fibroid Drugs Market Size, Share | Industry Report [2034] - Fortune Business Insights","headline":"Uterine Fibroid Drugs Market Size, Share | Industry Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1kNThzU1RrU09sakFCdlJaOXVVZnZhcjg2OXpIajhaMEk4N25DaF95YXo0Tk9ZakdYRl92bnBLcXZmdkZJaG1YZzVCSFVmSFRmdHpybHhTMEdVQTJQZFNDb1dXYzExZw?oc=5","date":"2025-10-30","type":"pipeline","source":"MedPage Today","summary":"Novel Oral miR-124 Enhancer Improves Remission in Refractory UC - MedPage Today","headline":"Novel Oral miR-124 Enhancer Improves Remission in Refractory UC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9sUFVGQTlTaXJSeE54eTZsQk5rRnBONXNEeE1VQ0dkbmxEa2hjTEJLcUt1amtQdjVIR2xEOHl4YjA2SmdCbEJIU2VmazBLYlpuZUswN0Q2SnpfMTQ2S0k1cUotdllWaTBO?oc=5","date":"2025-10-09","type":"regulatory","source":"Wiley Online Library","summary":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study) - Wiley Onli","headline":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPM0JRNGN2NVhQUnBOdkFaMU55cjhSM2JCRWVnSlFUcEFWSlpQZHdPN1pSanI1eU80Tmd4OEFidFZyZVNXSWdYY3dkZVd1MjZ4QmEtaGI2RXFRcWlPSy02N091enh0U3FTdzRuZlpKYVRnMHRYWkM4WUdlY2ZGZ0tRM0pHQXBGQ0dVeVplTktzdnoxazdQY09YX2tLZDFmSHZ4LWNvZ0RUbjZ5bVlOcl90U3EybDd2emcyM1E5ajRsbmp4SzYtb3ZZSzhyaExWUFJ0cWx3cHJ6RVlNbWE3NmE3VklEVEFNazRPcWhvUXp5OG1QN2gxUEw1di1Pbm1mbmZXRFlINTdzQTQ?oc=5","date":"2025-10-07","type":"pipeline","source":"PR Newswire","summary":"Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to \"Linzagolix\" for Uterine Fibroid Treatment - PR Newswire","headline":"Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to \"Linzagolix\" for Uterine Fibroid Treat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwNBVV95cUxOTmhIRkp5N0t4elpGRTlFUmc3YVR2QzRSbm51cG0zRTZGQWhXSHFFMGFuUFRaNnpmM2JfeGJmekdLOEcwcVhsSklHY1prLWpxR3ZNUWtDLXJwNzk5QTlUR2dPZHJQZXVCN3phTTUwLTlKQ1JOUzdjbGZvX1ZwQ2pVRGRZTUkzRzdyWGgza0JPNXp3QkhBZmY1akdXeGhvU016dXFwVkhjNlliOHpESVJjUV91cWNTUGs2Vks3TVNvdXdTYXlVallCX2VhTUVydWxEazgyYnNyN1pNWkNscnVpRkc2V1NqQVFEWVhoUnB3LXpTTmZobV9GbzhmaEN4ZF9lbXR0aHFITHFIenZZNC1mT2dTTE9sZlItQ0plR2xsXy1NTXgtNEVtWV9QWTFiM2dGYUVBSjZwLUtrYXRBV2JSaE5CSF9fZzhVQ3RSb3RjMWg5SDlYQkgtZGRmM3o4ZnRuajdkZTdHczVwYnduLUJuN1o5ZTZkODhFQW5XWlA3bTR4QmdtSHRwQmZaRVhJRm8?oc=5","date":"2025-07-30","type":"deal","source":"BioSpace","summary":"Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and ","headline":"Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbXNQbUR5OGVBRHV3UnhZNWlLdGliVThyWlJ2TmQ1dzNUVjIxNFQ2ZGpHRzV3cVU0ZjF4aC1OZjQ5MWxmV0JJUkwyVC1LSGFWY09VMnItWkMyVXFFc0dxWERkcXBGc08wUml0Rk0zTXE2VnhHWWNSbkxxYXVZSmNVWGxWTWJtX2o1YkJuR0d1X2FkcWZRaGVoSU14MHpyRXdRVGp6U0dnaVFTZw?oc=5","date":"2025-07-30","type":"pipeline","source":"Fierce Biotech","summary":"Kissei pays Viridian $70M to challenge Amgen for Japanese eye disease market - Fierce Biotech","headline":"Kissei pays Viridian $70M to challenge Amgen for Japanese eye disease market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTWc4NS01V0JwaDlqV0ZIbFBNbEZneDI0b3E2YkpjckpVV3JuNUMtSjk3M3pNMHFwM05ERW9zMlBBTmtoeTNuZVI0dFdzb2JKY2J4ZzFOMXhYMzRVakZ2aWYtMVlpQnBUTTc0WlRKQ0wzVFVNV0ZEZHZiMFQ5RElPY2hBRVNCR1BWdm1oTEJwcXFsVklnTTZwUWFlc0x0aVlzemJUNUlQVXhLNEZCbXJuZmhfT253cTZr?oc=5","date":"2024-09-12","type":"pipeline","source":"Asia Research News |","summary":"BMI’s relation to cancer therapy mortality risks not so straightforward - Asia Research News |","headline":"BMI’s relation to cancer therapy mortality risks not so straightforward - Asia Research News |","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPc184ek9Dek5sUmxhSDNjdkw3NHppMmdESGdHbjB4ZV9ybVpKLWotWllaX2JGb1dSQlFickdXMmJ5NklWeDBOSTBGaFM0TE5jcTliWUxIUkNlTVZUS0tsbUkxZTl1Uk1PLXY2TlF6Y0FKZGVnWUpObDVXazdrSmx5Wk9qQk9iZUNxQ3c5b3Q0NzRnWTl1T1YtbHRwVFVZXy1GX3kzY0Z4S3d3MW43QW5MdlIzNHZHdGJpZUhOeG9yNEtTdjhGVHFfTWJfTzRvaWdHS1I4aE55d1k5Wnd0Q1RQNmdtaVBLSE50RWR1RnJpLS1BSU50ckwxa2FXdlNWbTA?oc=5","date":"2024-09-03","type":"pipeline","source":"PR Newswire","summary":"Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan - PR Newswire","headline":"Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"marketed":2,"phase_2":3,"phase_3":6},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}